Swiss Osteoporosis Registry – improving osteoporosis treatment

The Swiss Osteoporosis Registry was founded in 2015 with the aim of improving osteoporosis treatment. It is a national, prospective registry for recording and monitoring people with osteoporosis or reduced bone density, but individuals with healthy bones are also included and monitored over time.

Individuals who undergo bone density measurement (known as DXA measurement, dual-energy X-ray absorptiometry) at one of the > 10 participating registry centres and give their written consent are continuously enrolled to the registry. Participants are followed up approximately every 2–3 years as part of routine clinical care.

The registry is used to research fracture risk prediction and the efficacy and safety of various osteoporosis therapies (including long-term outcomes, sequential therapies and rebound effects). In addition, quality aspects of DXA diagnostics and therapy application as well as cost effectiveness questions are investigated.

Promoting young talent in the Swiss Osteoporosis Registry

We are particularly committed to promoting young scientists. The Swiss Osteoporosis Registry offers students and doctoral candidates the opportunity to gain initial practical experience in handling registry data and in conducting and publishing registry studies.

The use of register data is generally free of charge for students and doctoral candidates. In addition, we provide support in obtaining ethical approval, preparing a statistical analysis plan, and writing and submitting scientific manuscripts.

If you are interested, please contact the Executive Board directly.

Links

1. Impact of FRAXplus adjustments versus FRAX on Fracture Risk Classification in the Swiss Osteoporosis Registry: Comparison of fracture risk assessment using the standard FRAX tool and the adapted FRAXplus version – implications for risk classification and treatment recommendations.

2. Response to the Letter to the Editor regarding “The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland” by Yang and colleagues – PubMed Discussion on the use of romosozumab in pretreated vs. treatment-naive patients.

3. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland – PubMed Initial experiences with the efficacy of romosozumab in Switzerland – a multicentre, prospective cohort study.

4. Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study – PubMed Long-term effect of Teriparatide over up to 10 years – based on registry data.

5. Fracture risk prediction in postmenopausal women with traditional and machine learning models in a nationwide, prospective cohort study in Switzerland with validation in the UK Biobank – PubMed Improvement of fracture prediction by comparing traditional tools (FRAX, TOP) with AI-based models – including validation in the UK Biobank.

6. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study – PubMed Comparative study between different antiresorptive substances.